Germany’s Merck counterbid for Versum drops prices
German healthcare company Merck KGaA, which manufactures medicines and laboratory supplies, has made a $5.9 billion counterbid for Versum Materials. Merck intends to use the deal to strengthen its electrochemical activities.
Merck’s share price reacted to the news on Wednesday with a significant discount of more than four percent.
From a chart technical point of view, the share broke through its upward trend line with a momentum candle yesterday. The range between €89 and €93.7 is now decisive for further share price development. The area around €89 should provide initial support, but if not, the picture will cloud over. If there is breakthrough downwards through this range, the next support could be in the area of €85. If the stock breaks through there as well, the area around €82 could offer further support.
The MACD indicator turned in on Tuesday and was naturally strengthened by the sharp downward movement.
With the strong downward movement, the 38- and 50-day smoothing lines crossed, which could be an additional sign of short-term price weakness.
If the bulls regain control, and the stock returns to near its trend line and the €93.7 area, then there is potential for further rising prices in the €97.65 area. If the bulls provide sufficient momentum for further price rises, prices in the range of €101 could be possible.
MRK.GE Daily Chart | Source: ActivTrader
Written by Daniel Schuetz, External Analyst
*The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and as such is to be considered to be a marketing communication.
All information has been prepared by ActivTrades PLC (“AT”). The information does not contain a record of AT’s prices or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance is not a reliable indicator of futures performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at its own risk.